Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

Rhea-AI Summary

Bright Minds Biosciences (BMBIF), a biotechnology company, announced its participation in the 2021 LD Micro Invitational XI, where Ian McDonald, CEO, and Dr. Gideon Shapiro, VP of Discovery, will present on June 10, 2021, at 12:30 PM ET. The presentation will focus on developing new treatments for neuropsychiatry disorders, epilepsy, and pain, utilizing next-generation serotonin agonists. The event will be broadcast live, with a replay available for seven days. Bright Minds aims to deliver effective therapies that enhance the therapeutic aspects of serotonergic compounds while minimizing side effects.

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery, will be presenting at the 2021 LD Micro Invitational XI, as follows:

Date:	Thursday, June 10, 2021
Time:	12:30PM Eastern Time
Webcast:	https://ldmicrojune2021.mysequire.com/

The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.

About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Investor Contact:
Judy DiClemente
jdiclemente@insitecony.com

FAQ

When is Bright Minds Biosciences presenting at the LD Micro Invitational XI?

Bright Minds Biosciences will present on June 10, 2021, at 12:30 PM Eastern Time.

Where can I watch the Bright Minds presentation from the LD Micro Invitational XI?

The presentation can be viewed live and for seven days thereafter at https://ldmicrojune2021.mysequire.com/

What are the main focuses of Bright Minds Biosciences?

Bright Minds focuses on developing novel treatments for neuropsychiatry disorders, epilepsy, and pain using next-generation serotonin agonists.

What advancements is Bright Minds making in treating mental health disorders?

Bright Minds is developing targeted therapies that enhance the therapeutic effects of serotonergic compounds while minimizing side effects.

Who are the key presenters for Bright Minds at the LD Micro Invitational?

Ian McDonald, CEO, and Dr. Gideon Shapiro, VP of Discovery, will be presenting for Bright Minds.